ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2016
Perspectives of health care professionals on cancer cachexia: results from three global surveys.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nutritional Interventions to Improve Clinical Outcomes in Ovarian Cancer: A Systematic Review of Randomized Controlled Trials.Nutrients · 2019Pooled it
- A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.Journal of cachexia, sarcopenia and muscle · 2018Trial
- Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.Cancer cell · 2026Review
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- Associations of dyadic appraisal of cancer cachexia symptoms with psychological distress and quality of life in dyads of palliative care patients: a longitudinal mixed-methods study protocol.BMC palliative care · 2025Article
- Weight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events-Dangerous and Misleading.Journal of cachexia, sarcopenia and muscle · 2025Review
- A Novel Definition and Grading Diagnostic Criteria for Tumour-Type-Specific Comprehensive Cachexia Risk.Journal of cachexia, sarcopenia and muscle · 2025Article
- Prognostic impact of visceral and subcutaneous fat area in stage I-III colon cancer patients with cachexia: a population-based multicenter study.Frontiers in nutrition · 2025Article
- Factors Associated with Multimodal Care Practices for Cancer Cachexia among Pharmacists.Current oncology (Toronto, Ont.) · 2024Article
- AWGC2023 cachexia consensus as a valuable tool for predicting prognosis and burden in Chinese patients with cancer.Journal of cachexia, sarcopenia and muscle · 2024Article
- Factors associated with multimodal care practices for cancer cachexia among registered dietitians.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey.Journal of cachexia, sarcopenia and muscle · 2024Article
- Healthcare professionals' knowledge of and compliance with the ASCO/ESMO/GLIM guidelines for the diagnosis and management of cancer cachexia (CC): the ASSIST-CC baseline findings in Uganda.Ecancermedicalscience · 2024Article
- What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Holistic multimodal care for patients with cancer cachexia and their family caregivers.Asia-Pacific journal of oncology nursing · 2023Review
- Variable body and tissue weight reporting in preclinical cachexia literature may alter study outcomes and interpretation.Disease models & mechanisms · 2023Article
- Health care professionals' experiences of dealing with cancer cachexia.International journal of clinical oncology · 2023Article
- Perspectives of registered dietitians and factors associated with their personal accomplishment in the management of cancer cachexia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Identification and management of cancer cachexia in patients: Assessment of healthcare providers' knowledge and practice gaps.Journal of cachexia, sarcopenia and muscle · 2022Article
- Clinical and economic value of oral nutrition supplements in patients with cancer: a position paper from the Survivorship Care and Nutritional Support Working Group of Alliance Against Cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCachexia has a high prevalence in cancer patients and negatively impacts prognosis, quality of life (QOL), and tolerance/response to treatments. This study reports the results of three surveys designed to gain insights into cancer cachexia (CC) awareness, understanding, and treatment practices among health care professionals (HCPs).
methodsSurveys were conducted globally among HCPs involved in CC management. Topics evaluated included definitions and synonyms of CC, diagnosis and treatment practices, and goals and desired improvements of CC treatment.
resultsIn total, 742 HCPs from 14 different countries participated in the surveys. The majority (97%) of participants were medical oncologists or hematologists. CC was most frequently defined as weight loss (86%) and loss of appetite (46%). The terms loss of weight and decreased appetite (51% and 34%, respectively) were often provided as synonyms of CC. Almost half (46%) of the participants reported diagnosing CC and beginning treatment if a patient experienced a weight loss of 10%. However, 48% of the participants would wait until weight loss was ≥15% to diagnose CC and start treatment. HCPs also reported that 61%-77% of cancer patients do not receive any prescription medication for CC before Stage IV of disease is reached. Ability to promote weight gain was rated as the most important factor for selecting CC treatment. Key goals of treatment included ensuring that patients can cope with the cancer and treatment and have a QOL benefit. HCPs expressed desire for treatments with a more CC-specific mode of action and therapies that enhance QOL.
conclusionsThese surveys underscore the need for increased awareness among HCPs of CC and its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.